Zacks Investment Research·2d ago
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's DayFour biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Biogen's growth portfolio, which delivered 24% YoY revenue growth in Q2 2026, is offsetting legacy multiple sclerosis erosion, but total revenue growth remains modest at 3.4%. Gross margin volatility, swinging from 78.3% in Q1 2024 to 56.9% in Q2 2026, suggest...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth is mixed at 3.4% YoY in Q2 2026, with gross margin compressing to 56.9% from 78.3% in Q1 2024, reflecting a shift toward lower-margin products and inconsistent operating leverage (op margin 11.6% in Q2 2026).
Biogen is a leading biotechnology company pioneering innovative science to deliver transformative medicines, enhancing patient lives and shareholder value.
Specializing in neurological diseases, Biogen has a strong foothold in a critical and growing segment of the healthcare market.
With key patents expiring soon, Biogen is actively looking to expand its pipeline to sustain long-term growth.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | $3.60+22.4% vs $2.94 | $2.7B+11.2% vs $2.5B |
Q2 2026 Apr 29, 2026 | $3.57+17.0% vs $3.05 | $2.5B+8.4% vs $2.3B |
Q1 2026 Feb 6, 2026 | $1.99+22.1% vs $1.63 | $2.3B+3.5% vs $2.2B |
Q4 2025 Oct 30, 2025 | $4.81+24.0% vs $3.88 | $2.5B+4.9% vs $2.3B |
Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
Biogen (NASDAQ: BIIB - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, profitability, valuation and earnings. Insider and Institutional Ownership 87.9% of Biogen shares are held
CAMBRIDGE, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI® (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology (CJASN). The dedicated subgroup analysis was first presented at the 2025 Annual Meeting of the European Society of Paediatric Nephrology (ESPN).
Corient Private Wealth LP raised its stake in shares of Biogen Inc. (NASDAQ: BIIB) by 14.7% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 42,397 shares of the biotechnology company's stock after acquiring an additional 5,445 shares during the period. Corient Private Wealth LP's holdings
Benchmark BIIB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Biogen Inc. (BIIB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $225.36 | $33.3B | 25.52 | 1.39% | 13.18% | 7.4% | — | |
| $803.90 | $82.82B | 19.38 | 0.99% | 27.86% | 18.49% | — | |
| $514.99 | $130.71B | 33.62 | 9.57% | 34.89% | 23.31% | — | |
| $63.37 | $12.25B | 35.21 | 12.87% | 2.14% | 1.18% | — | |
| $251.65 | $33.6B | 108.00 | 65.19% | 16.82% | 93.61% | — | |
| $152.67 | $189.55B | 22.52 | 2.39% | -10.64% | -16.35% | — |
Biogen Inc. (BIIB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Biogen Inc. (BIIB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 1, 2026·SEC
Jun 10, 2026·SEC
Get notified when BIIB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Biogen Inc. (BIIB) stock FAQ — growth, dividends, profitability & financials explained
Biogen Inc. (BIIB) reported $9.95B in revenue for fiscal year 2025. This represents a 3490% increase from $277.1M in 1996.
Biogen Inc. (BIIB) grew revenue by 1.4% over the past year. Growth has been modest.
Yes, Biogen Inc. (BIIB) is profitable, generating $835.1M in net income for fiscal year 2025 (13.2% net margin).
Biogen Inc. (BIIB) has a return on equity (ROE) of 7.4%. This is below average, suggesting room for improvement.
Biogen Inc. (BIIB) generated $2.97B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
